secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2022-01-11T23:59:59+00:00
Accession:  0001193125-22-006746
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace reports preliminary Q4 2021 revenue of $11.0M (+2% YoY); FY2021 $45.2M (+10% YoY)
--------------------------------------------------------------------------------

- Q4 2021 revenue ~$11.0M (+2% YoY); initial implant $8.5M (+10%), replacement $2.5M (-19%).
- FY2021 revenue ~$45.2M (+10% YoY); initial implant $33.7M (+20%), replacement $11.5M (-12%).
- 150 centers performed RNS implant in 2021, up 14% from 132 centers in 2020.
- Enrolled first patient in adolescent study to expand indications beyond current pool.
- Full Q4 and FY results expected in mid-March 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000119312522006746/0001193125-22-006746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000119312522006746/d276070d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-006746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer